INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of September 30, 2017 and December 31, 2016:

	September 30, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(7,988	)	$	23,963		12
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		1,247,181		(153,216	)		1,093,965		15.25
Hormone therapy drug candidate patents (pending)		1,474,061		—			1,474,061		n/a
Non-amortizing intangible assets:
Multiple trademarks		201,432		—			201,432		indefinite
Total	$	3,046,368	$	(252,947	)	$	2,793,421

	December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA® software patent	$	31,951	$	(6,490	)	$	25,461		12.75
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		1,093,452		(102,393	)		991,059		16
Hormone therapy drug candidate patents (pending)		1,203,987		—			1,203,987		n/a
Non-amortizing intangible assets:
Multiple trademarks		185,465		—			185,465		indefinite
Total	$	2,606,598	$	(200,626	)	$	2,405,972

Schedule of estimated amortization expense

Estimated amortization expense for the next five years for the patent cost currently being amortized is as follows:

Year Ending December 31,		Estimated Amortization
	2017(3 months)	$	18,433
	2018	$	73,732
	2019	$	73,732
	2020	$	73,732
	2021	$	73,732
	Thereafter	$	804,567